Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.33 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195553 | 0.79 | CCR1 (0.48) | CCR1CCR5CCR8HDAC6P4HA1 | |
| SCHEMBL4381210 | 0.75 | CCR1 (0.44) | CCR1CCR5CCR8HDAC6P4HA1 | |
| Bromide SCHEMBL197909 | 0.75 | CCR1 (0.44) | CCR1CCR5CCR8HDAC6P4HA1 | |
| SCHEMBL197910 | 0.71 | CCR1 (0.41) | CCR1CCR5CCR8HDAC6P4HA1 | |
| SCHEMBL196847 | 0.71 | NR1H2 (0.42) | CCR1CCR5CCR8HDAC6P4HA1 | |
| SCHEMBL197285 | 0.70 | CCR1 (0.39) | CCR1CCR5CCR8HDAC6P4HA1 | |
| SCHEMBL4383260 | 0.70 | NR1H2 (0.43) | CCR1CCR5CCR8HDAC6P4HA1 | |
| SCHEMBL198141 | 0.70 | ESR1 (0.54) | CCR1CCR5CCR8HDAC6P4HA1 | |
| SCHEMBL29664590 | 0.68 | CCR1 (0.42) | CCR1CCR5CCR8HDAC6P4HA1 | |
| SCHEMBL2991234 | 0.67 | KDM4E (0.56) | CCR1CCR5CCR8P4HTMMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084608-B2 | 2,2′ -bipyridine derivative having a reactive silyl group, its production method, and transition metal complex | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090299068-A1 | 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2128165-A1 | 2, 2´-bipyridine derivatives having reactive silyl group, production methods, transition metal complexes thereof | Shin-Etsu Chemical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299068-A1 | 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX | CBR3, TST, HRH3 | CCR1 380/4885CCR5 272/4885CCR8 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.